MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study
Titel:
MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study
Auteur:
Hu, Shimin Xu-Monette, Zijun Y. Wu, Lin Visco, Carlo Tzankov, Alexander Montes-Moreno, Santiago Dybkær, Karen Chiu, April Orazi, Attilio Zu, Youli Bhagat, Govind Richards, Kristy L. Hsi, Eric D. Zhao, X. Frank Choi, William W.L. Zhao, Xiaoying Zhang, Xiaohong Han van Krieken, J. Huang, Qing Huh, Jooryung Ai, Weiyun Ponzoni, Maurilio A. Ferreri, Andres J.M. Zhou, Fan Winter, Jane N. Go, Ronald S. Li, Yong Piris, Miguel A. Møller, Michael B. Miranda, Roberto N. Medeiros, L. Jeffrey Young, Ken H.